Approval · Notice of Compliance 1095 · 2000
DIGIBIND: Notice of Compliance 1095
Issued August 24, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1095
- Date
- August 24, 2000
- Company
- Glaxo Wellcome Inc.Mississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in manufacturing - new integrated production facility - new continuous flow centrifugation step
- Therapeutic class
- Specific antibody for digoxin
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DIGIBIND | Not yet assigned | — |
Medicinal ingredients
- DIGOXIN IMMUNE FAB (OVINE) 38 MG per VIAL